This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (31)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Movement Disorders  • Parkinson Disease/ Parkinsonian Disorders  • Drug Therapy  • Adverse Effects  • Alert me on articles by topic

Padraig E. O'Suilleabhain, MB; Richard B. Dewey, Jr, MD

Arch Neurol. 2002;59:986-989.

Background  Excessive daytime somnolence is a common report among patients who have Parkinson disease (PD). The relative contributions of disease severity and of the various dopaminergic drugs are unclear.

Objective  To separate and quantify the contributions of disease markers and drug doses.

Methods  Patients seen during a 7-month period at a center for movement disorders completed the Epworth Sleepiness Scale. Treatment subgroups were compared. The relationship to sedation of age; dopaminergic drug classes and doses; Hoehn and Yahr stage; duration of disease; total score on the motor subsection of the Unified Parkinson Disease Rating Scale; and the presence or absence of dementia, depression, or hallucinations was calculated using simple and multiple regression and t tests.

Results  The Epworth Sleepiness Scale scores were higher among patients with PD (mean [SD], 10.8 [5.3]; n = 368) compared with patients with other neurological disorders (mean, 8.5 [5.1]; n = 243; P<.001). A model containing the Hoehn and Yahr stage, levodopa dose, and use of a dopamine agonist was the best at predicting the total score of Epworth Sleepiness Scale in patients who have PD, but accounted for only 9% of the interindividual variance. The parameter estimates (SE) corresponded to a 1.02 (0.03)–point increase per Hoehn and Yahr stage, a 0.14 (0.06)–point increase per 100-mg increase in levodopa dose over 24 hours, and a 2.33 (0.57)-point increase with use of an agonist. There was no statistically significant dose response for agonists. No statistically significant difference in sedation among the commonly used dopamine agonists was found.

Conclusions  Somnolence in patients with PD, which is on average 25% higher than in other neurological diseases, is related to PD stage, levodopa dose, and the use of a dopamine agonist. However, most of the variability in sedation levels in patients with PD as well as in controls is the result of, as yet, unidentified factors.

From the Clinical Center for Movement Disorders, Department of Neurology, University of Texas Southwestern Medical School, Dallas.

RELATED ARTICLE

Archives of Neurology Reader's Choice: Continuing Medical Education
Arch Neurol. 2002;59(6):1048-1050.
FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Risk factors for somnolence, edema, and hallucinations in early Parkinson disease
Biglan et al.
Neurology 2007;69:187-195.
ABSTRACT | FULL TEXT  

Transdermal Rotigotine: Double-blind, Placebo-Controlled Trial in Parkinson Disease
Jankovic et al.
Arch Neurol 2007;64:676-682.
ABSTRACT | FULL TEXT  

Cardiac Valve Regurgitation With Pergolide Compared With Nonergot Agonists in Parkinson Disease
Dewey et al.
Arch Neurol 2007;64:377-380.
ABSTRACT | FULL TEXT  

Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers
Samuels et al.
J Psychopharmacol 2006;20:756-770.
ABSTRACT  

The two faces of Eve: Dopamine's modulation of wakefulness and sleep
Rye
Neurology 2004;63:S2-S7.
ABSTRACT | FULL TEXT  

Fluctuations in cognition and alertness in Parkinson's disease and dementia
Serrano and Garcia-Borreguero
Neurology 2004;63:S31-S34.
ABSTRACT | FULL TEXT  

Low levels of ventricular CSF orexin/hypocretin in advanced PD
Drouot et al.
Neurology 2003;61:540-543.
ABSTRACT | FULL TEXT